Ingredient guide · Ingredient reference

CoQ10 and AF: a small heart-failure trial needs narrow interpretation

An adjunct study recorded fewer atrial-fibrillation episodes in its CoQ10 group. The findings do not establish stroke prevention or a replacement for AF treatment.

Read the evidence ↓

Supplement Science Insights Editorial Team

Published September 23, 2026

What the study found

One hundred two people with heart failure were randomized to usual medicines with or without CoQ10. Twenty-four-hour Holter monitoring and other assessments were performed before treatment and at six and twelve months. [1]

At twelve months, AF episodes were reported in three CoQ10 participants and twelve controls. The small number of events and intermittent monitoring limit how completely the study can characterize rhythm burden. [1]

What remains unanswered

The abstract does not establish a matching placebo or blinding. Its findings concern adjunct treatment in heart failure, not every person with AF. Funding and conflicts were not established, and no stroke-prevention or anticoagulant-replacement conclusion follows. [1]

A hypothetical distinction

Imagine two brief monitoring windows record different event counts. Those observations matter, but they do not continuously measure every rhythm event between visits.

Evidence summary — CoQ10 and AF
DetailInterpretation
102 patientsHeart-failure population
Intermittent HolterLimited observation windows
Stroke preventionNot established
CoQ10 and AF: a small heart-failure trial needs narrow interpretation — original article outline diagram
Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

  1. Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure - PubMed
    Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.